title: Spontaneous pulmonary hemorrhage following coronary thrombolysis.
abstract: Excessive bleeding is a major concern during the administration of thrombolytic therapy. Although the great majority of these events occur at sites of vascular interruption, major gastrointestinal, retroperitoneal, genitourinary, and central nervous system hemorrhage are known to occur. We present a patient who developed spontaneous pulmonary hemorrhage during thrombolytic therapy. Lack of recognition that the lungs too may be a site of spontaneous hemorrhage during thrombolytic therapy may lead to a considerable diagnostic and therapeutic delay. Pulmonary hemorrhage should be considered in the differential diagnosis of patients who receive thrombolytic therapy in whom new roentgenographic pulmonary infiltrates present accompanied by decreases in hematocrit value.
authors.affiliation: Division of Cardiology, Long Island College Hospital, Brooklyn.
authors.forename: P E
authors.initials: PE
authors.lastname: Nathan
authors.forename: A V
authors.initials: AV
authors.lastname: Torres
authors.forename: A J
authors.initials: AJ
authors.lastname: Smith
authors.forename: A J
authors.initials: AJ
authors.lastname: Gagliardi
authors.forename: K B
authors.initials: KB
authors.lastname: Rapeport
mesh_terms: D000328:Adult; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000150:complications / Q000188:drug therapy*; D006469:Hemoptysis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects*
chemical_list: D014568:Urokinase-Type Plasminogen Activator